ReviewCancers2020
Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- A Rare Case of Occult Small-cell Lung Cancer with Initial Manifestations of Brain Metastases.Internal medicine (Tokyo, Japan) · 2026Article
- Diagnostic and Therapeutic Strategies for Brain Metastases from Unknown Primary Tumors: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Histogram Analysis and Heterogeneous Radial Changes Using ADC Map Images in Metastatic Brain Tumors for Dose Painting Intent.Advanced biomedical research · 2026Article
- A large scale multi-dataset investigation of brain metastases distribution based on primary cancer type.BMC cancer · 2025Article
- Multiparametric MRI characteristics for differentiating primary cancer origin in brain metastases.BMC medical imaging · 2025Article
- Article
- Radiomics based on brain-to-tumor interface enables prediction of metastatic tumor type of brain metastasis: a proof-of-concept study.La Radiologia medica · 2025Article
- Breaking boundaries: role of the brain barriers in metastatic process.Fluids and barriers of the CNS · 2025Review
- Dose-Incorporated Deep Ensemble Learning for Improving Brain Metastasis Stereotactic Radiosurgery Outcome Prediction.International journal of radiation oncology, biology, physics · 2024Article
- Brain Metastasis in the Emergency Department: Epidemiology, Presentation, Investigations, and Management.Cancers · 2024Review
- From pre-clinical to translational brain metastasis research: current challenges and emerging opportunities.Clinical & experimental metastasis · 2024Review
- Squash surprise in an elderly female.CytoJournal · 2024Article
- Patient reported outcomes following whole brain radiotherapy in patients with brain metastases in NSIA-LUTH Cancer Center.BMC cancer · 2023Article
- Deep Learning for Detecting Brain Metastases on MRI: A Systematic Review and Meta-Analysis.Cancers · 2023Review
- Novel Therapeutic Approaches in Neoplastic Meningitis.Cancers · 2022Review
- Prognostic factors among patients with brain metastases from cancer of unknown primary site.Journal of neuro-oncology · 2022Article
- Article
- Current Advances and Challenges in Radiomics of Brain Tumors.Frontiers in oncology · 2021Review
- Small RNA Sequencing Identifies a Six-MicroRNA Signature Enabling Classification of Brain Metastases According to their Origin.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases (BMs) are the most common intracranial tumours in adults and occur up to 3-10 times more frequently than primary brain tumours. BMs may be the cause of the neurological presenting symptoms in patients with otherwise previously undiagnosed cancer. In up to 15% of patients with BMs, the primary tumour cannot be identified. These cases are known as BM of cancer of unknown primary (CUP) (BM-CUP). CUP has an early and aggressive metastatic spread, poor response to chemotherapy, and poor prognosis. The pathogenesis of CUP seems to be characterized by a specific underlying pro-metastatic signature. The understanding of BM-CUP, despite its relative frequency and unfavourable outcome, is still incomplete and clear indications on management are missing. Advances in diagnostic tools, molecular characterization, and target therapy have shifted the paradigm in the approach to metastasis from CUP: while earlier studies stressed the importance of finding the primary tumour and deciding on treatment based on the primary diagnosis, most recent studies focus on the importance of identifying targetable molecular markers in the metastasis itself. The aim of this review is to summarize current evidence on BM-CUP, from the diagnosis and pathogenesis to the treatment, with a focus on available studies and ongoing clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.